Shares of Catalyst Pharmaceuticals Inc. CPRX rose 1.34% to $23.40 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.19% to 19,692.33 and the Dow Jones Industrial Average DJIA rising 0.71% to 44,873.28.

Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target of $28.00. The firm highlighted Catalyst Pharma's successful commercialization of drugs for rare neurological diseases as the basis for the positive outlook.

Fintel reports that on February 4, 2025, Baird initiated coverage of Catalyst Pharmaceuticals (NasdaqCM:CPRX) with a Outperform recommendation. Analyst Price Forecast Suggests 47.68% Upside As of January 29,